Raymond James Maintains Outperform on HealthEquity, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst C. Gregory Peters has reaffirmed an Outperform rating on HealthEquity (NASDAQ:HQY) and increased the price target from $90 to $95.

December 13, 2023 | 6:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HealthEquity's Outperform rating is maintained by Raymond James, with a raised price target from $90 to $95, indicating a positive outlook on the stock.
The reaffirmation of the Outperform rating by a reputable analyst, along with an increased price target, typically signals a bullish sentiment on the stock, suggesting a potential rise in its price in the short term. Investors often view such updates as a sign of continued company strength and future growth prospects.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100